Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 411 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Stereotactic body radiation therapy/radiosurgery (SBRT) Clear all
Completed Not applicable Interventional Results available

Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung

NCT00832780
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Solid Tumors
Interventions
Stereotactic Body Radiation
Radiation
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 13, 2026, 10:36 PM EDT
Recruiting Phase 2 Interventional

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

NCT06048484
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat, Etrumadenant, Modified FOLFIRINOX
Radiation · Drug
Lead sponsor
Gulam Manji
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Lake Success, New York • New York, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 13, 2026, 10:36 PM EDT
Active, not recruiting Not applicable Interventional

TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer

NCT04552509
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Body Radiotherapy
Radiation
Lead sponsor
Linda Chan, MD
Other
Eligibility
Male only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 13, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer

NCT02572284
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), Prostatectomy, Quality of Life Questionnaires
Radiation · Procedure · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 13, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant

NCT02182687
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
Radiation · Procedure · Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 13, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

NCT03220854
View directory record Official record
Conditions
Solid Tumor
Interventions
Stereotactic radiotherapy, Biological: humanized anti-PD-1 monoclonal antibody, Biological: humanized anti-PD-L1 monoclonal antibody
Radiation · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 13, 2026, 10:36 PM EDT
Terminated Phase 1 Interventional

High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma

NCT01378481
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
Interventions
Vorinostat, Stereotactic Radiosurgery, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 13, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

Stereotactic Radiation Therapy in Treating Patients With Brain Metastases

NCT00006259
View directory record Official record
Conditions
Metastatic Cancer
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 13, 2026, 10:36 PM EDT
Not listed Not applicable Interventional

Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery

NCT02446366
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage IIB Prostate Cancer, Stage III Prostate Adenocarcinoma
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Other · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 13, 2026, 10:36 PM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

NCT02858869
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage IV Non-Small Cell Lung Cancer, Stage IV Skin Melanoma, Melanoma of Unknown Primary
Interventions
Pembrolizumab, Stereotactic Radiosurgery
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 13, 2026, 10:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

NCT01217411
View directory record Official record
Conditions
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 13, 2026, 10:36 PM EDT
Not yet recruiting Not applicable Interventional

SOLIS: Single-Dose Radiotherapy With Omission of Lumpectomy for Intact Small Breast Cancers

NCT07844759
View directory record Official record
Conditions
Breast Cancer, Early-Stage Breast Carcinoma, Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Interventions
Stereotactic Radiation Therapy, Endocrine Therapy
Radiation · Drug
Lead sponsor
Renaissance Institute of Precision Oncology and Radiosurgery
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 13, 2026, 10:36 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

NCT04214262
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
391
States / cities
Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

NCT03635164
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Durvalumab, Stereotactic Body Radiation Therapy (SBRT), Standard of Care Therapy
Drug · Radiation · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 13, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN

NCT02057107
View directory record Official record
Conditions
Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions
SBRT, Cetuximab, Docetaxel
Radiation · Drug
Lead sponsor
Heath Skinner
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 13, 2026, 10:36 PM EDT
Completed Phase 1 Interventional

Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

NCT00946673
View directory record Official record
Conditions
Brain Cancer, Neoplasm Metastasis, Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
Vorinostat, Radiation Therapy
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Stanford, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 13, 2026, 10:36 PM EDT
Recruiting Not applicable Interventional

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

NCT04693377
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Prostate Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcoma, Metastatic Thyroid Gland Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Cryosurgery, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 13, 2026, 10:36 PM EDT
Recruiting Phase 2 Interventional

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

NCT04402151
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 90 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 13, 2026, 10:36 PM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma

NCT03991962
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 13, 2026, 10:36 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma

NCT01586182
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oropharynx
Interventions
Stereotactic Body Radiotherapy
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 13, 2026, 10:36 PM EDT
Recruiting Phase 2 Interventional

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

NCT06397703
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide, Degarelix or Relugolix, Stereotactic body radiation therapy/radiosurgery (SBRT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 13, 2026, 10:36 PM EDT
Terminated Not applicable Interventional Results available

Y90 Radiation Segmentectomy vs SBRT for HCC

NCT04235660
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Yttrium-90 Radiation Segmentectomy, Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 13, 2026, 10:36 PM EDT
Recruiting Phase 2 Interventional

Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)

NCT07227610
View directory record Official record
Conditions
Brain Metastases, Cancer (With CNS Involvement)
Interventions
Staged Stereotactic Radiosurgery (SSRS), Fractionated Stereotactic Radiotherapy (FSRT)
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 13, 2026, 10:36 PM EDT
Terminated Early Phase 1 Interventional

Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

NCT01525446
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
SBRT with proton beam radiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 13, 2026, 10:36 PM EDT